Eli Lilly’s New Pharmaceutical Products in 3Q17



New products from Lilly

Eli Lilly’s (LLY) new products include Basaglar, Cyramza, Jardiance, Lartruvo, Olumiant, Taltz, and Trulicity.

Article continues below advertisement


Basaglar is an insulin glargine injection approved for controlling blood sugar levels in patients with type-1 and type-2 diabetes. Eli Lilly reported Basaglar sales of $145.7 million for 3Q17, compared with $19.4 million in 3Q16. Of these sales, $115 million was reported from the US, while $31 million was reported from outside the US.


Cyramza is an oncology drug approved in combination with other drugs for the treatment of non-small cell lung cancer, colorectal cancer, and gastric cancer. Cyramza’s revenues rose ~23% growth in 3Q17 to $196.0 million. This growth was driven by a 4% rise in US sales and a 38% rise in sales outside of the US, including strong growth in Japan.

Article continues below advertisement


Jardiance is a part of Boehringer Ingelheim’s and Eli Lilly’s diabetes alliance. Jardiance reported sales of $127 million during 3Q17, driven by a $51-million rise in US sales and a $29-million rise in non-US sales.


Lartruvo is a drug approved for the treatment of patients with advanced soft-tissue sarcoma. Lartruvo reported sales of $54 million during 3Q17, with US sales of $42 million and non-US sales of $12 million.

Article continues below advertisement


Taltz reported revenues of $151 million during 3Q17, compared with $33 million during 3Q16. US sales came to $131 million, while non-US sales came to $20 million during 3Q17.


Trulicity reported a 117% rise in revenues to $528 million during 3Q17, compared with $244 million during 3Q16. US sales totaled $413 million, while non-US sales totaled $115 million during 3Q17.

Notably, the SPDR S&P Pharmaceuticals ETF (XPH) has 4.7% of its total holdings in Eli Lilly (LLY), 4.8% in Pfizer (PFE), 4.9% in Perrigo (PRGO), and 4.5% in Bristol-Myers Squibb (BMY).


More From Market Realist